HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Futura Extends Europe Licensing Agreement With Cooper For Eroxon ED Gel

Executive Summary

Futura Medical has extended its licensing agreement with Cooper Consumer Health for the rights to market its Eroxon topical, gel-based erectile dysfunction treatment throughout the European Economic Area, United Kingdom and Switzerland until 2029. 

You may also be interested in...



‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future

Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability. 

OTC Marketing Awards 2023: What The Judges Said About The Leading Entries

The trophies have been presented at the OTC Marketing Awards 2023 - but what did the judging panel have to say about the winning and highly-commended entries?

Female Sexual Dysfunction, China, Next On The Agenda For Eroxon Creator Futura

Drug-free erectile dysfunction “stimgel” creator Futura wants to see if the technology underpinning Eroxon can be applied to female sexual dysfunction. Breaking into China is also high up on the agenda for the UK-based R&D company's CEO James Barder, he reveals in this exclusive interview.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel